Press Releases

Date	Title
10/6/22	Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
9/26/22	Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
9/20/22	Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
8/10/22	Pulse Biosciences Reports Second Quarter 2022 Financial Results
8/4/22	Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
7/27/22	Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022
6/16/22	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/9/22	Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
6/3/22	Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
5/19/22	Pulse Biosciences, Inc. Announces Changes to its Rights Offering

Keyword Search